NCT07555301

Brief Summary

An observational study tracking the clinical course of patients with IgA nephropathy.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
44mo left

Started Jun 2026

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 21, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

April 29, 2026

Completed
1 month until next milestone

Study Start

First participant enrolled

June 1, 2026

Expected
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2028

1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2029

Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

2.6 years

First QC Date

April 21, 2026

Last Update Submit

April 21, 2026

Conditions

IgA Nephropathy (IgAN)

Outcome Measures

Primary Outcomes (1)

  • Change of Albuminuria

    What is the impact of sparsentan on Albuminuria

    36 months

Study Arms (1)

Patients with IgA Nephropathie and a therapy with Sparsentan

Drug: sparsentan

Interventions

sparsentanDRUG

Follow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR

Patients with IgA Nephropathie and a therapy with Sparsentan

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with IgA Nephropathy and therapy with sparsentan

You may qualify if:

  • IgA Nephropathy, Use of Sparsentan

You may not qualify if:

  • age \< 18y

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stadtspital Zurich

Zurich, Canton of Zurich, 8000, Switzerland

Location

MeSH Terms

Conditions

Glomerulonephritis, IGA

Interventions

sparsentan

Condition Hierarchy (Ancestors)

GlomerulonephritisNephritisKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

Andi Schleich

CONTACT

+41 44 416 21 55Andreas.schleich@stadtspital.ch

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

April 21, 2026

First Posted

April 29, 2026

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

December 31, 2028

Study Completion (Estimated)

December 31, 2029

Last Updated

April 29, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

according to patients wishes

Locations

CH(1)